Melphalan

Generic Name: Melphalan

Brand Names: Alkeran, Evomela, Phelinun, Pepaxti

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈Cl_₂N_₂O_₂

CAS Number: 148-82-3

Unique Ingredient Identifier: Q41OR9510P

Background: Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.

Indication: Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.

Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Associated Conditions: Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2

Conditions: Lymphoma

First Posted Date: 2009-05-25

Last Posted Date: 2013-08-02

Lead Sponsor: Cancer Research UK

Target Recruit Count: 47

Registration Number: NCT00908180

Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma

Phase 2

Conditions: Lymphoma

First Posted Date: 2009-05-22

Last Posted Date: 2013-08-02

Lead Sponsor: Cancer Research UK

Target Recruit Count: 49

Registration Number: NCT00907036

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Phase 2

Completed

Conditions: Transplantation, Autologous
Multiple Myeloma
Blood and Marrow Transplant (BMT)
Transplantation, Homologous

Interventions: Procedure: Autologous peripheral blood stem cells (auto-PBSC) transplantation
Procedure: Allogeneic peripheral blood stem cells (allo-PBSC) transplantation
Drug: Filgrastim
Drug: Cyclophosphamide
Drug: Melphalan
Drug: Cyclosporine
Radiation: Total lymphoid irradiation
Biological: Rabbit anti-thymocyte globulin
Drug: Mycophenolate Mofetil 250mg
Drug: Solumedrol
Drug: Diphenhydramine
Drug: Acetaminophen
Drug: Hydrocortisone

First Posted Date: 2009-05-12

Last Posted Date: 2017-10-20

Lead Sponsor: Stanford University

Target Recruit Count: 9

Registration Number: NCT00899847

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

Not Applicable

Completed

Conditions: Leukemia
Amyloidosis

Interventions: Drug: Lenalidomide
Drug: Melphalan
Drug: Dexamethasone

First Posted Date: 2009-04-30

Last Posted Date: 2017-03-22

Lead Sponsor: Stanford University

Target Recruit Count: 25

Registration Number: NCT00890552

Locations: 🇺🇸
Stanford University Cancer Institute, Stanford, California, United States

Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

Phase 1

Completed

Conditions: Hematologic Malignancies
Allogeneic Stem Cell Transplantation

Interventions: Drug: Fludarabine
Drug: Melphalan
Drug: Antithymocyte Globulin
Drug: Sirolimus
Drug: Tacrolimus

First Posted Date: 2009-04-29

Last Posted Date: 2013-10-08

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 12

Registration Number: NCT00890500

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

Phase 2

Active, not recruiting

Conditions: Myeloma

Interventions: Drug: Melphalan
Drug: Velcade
Drug: Thalidomide
Drug: Dexamethasone
Drug: Cisplatin
Drug: Adriamycin
Drug: Cyclophosphamide
Drug: Etoposide

First Posted Date: 2009-03-30

Last Posted Date: 2024-07-25

Lead Sponsor: University of Arkansas

Target Recruit Count: 160

Registration Number: NCT00871013

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Velcade
Drug: Melphalan
Drug: Thalidomide
Drug: Dexamethasone
Drug: Cisplatin
Drug: Adriamycin
Drug: Cyclophosphamide
Drug: Etoposide

First Posted Date: 2009-03-25

Last Posted Date: 2024-07-03

Lead Sponsor: University of Arkansas

Target Recruit Count: 90

Registration Number: NCT00869232

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

Not Applicable

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Angioimmunoblastic T-cell Lymphoma
Childhood Myelodysplastic Syndromes
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Childhood Diffuse Large Cell Lymphoma
Childhood Nasal Type Extranodal NK/T-cell Lymphoma

Interventions: Drug: fludarabine phosphate
Drug: melphalan
Radiation: total-body irradiation
Procedure: allogeneic hematopoietic stem cell transplantation
Biological: anti-thymocyte globulin

First Posted Date: 2009-03-05

Last Posted Date: 2019-11-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 62

Registration Number: NCT00856388

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide (Revlimid)
Drug: Melphalan
Drug: Dexamethasone

First Posted Date: 2009-02-13

Last Posted Date: 2017-07-19

Lead Sponsor: NYU Langone Health

Target Recruit Count: 8

Registration Number: NCT00843310

Locations: 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸
NYU Tisch Hospital, New York, New York, United States
🇺🇸
NYU Cancer Center, New York, New York, United States

Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2009-02-10

Last Posted Date: 2011-05-13

Lead Sponsor: Institut Paoli-Calmettes

Target Recruit Count: 135

Registration Number: NCT00840684

Locations: 🇫🇷
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy